Clinical Forum for Operational Excellence 2016

DIA27 - 28 October 2016, Dusseldorf, Germany.
Clinical Data, Clinical Operations and Statistics are highly dynamic groups in the clinical development arena. 2016 will bring important changes in the European regulatory framework once the ICH E6 Addendum kicks in with the following guidances:
  • Sponsors will be expected to implement a system to manage quality throughout the design, conduct, recording, evaluation, reporting and archiving of clinical trials.
  • The sponsor should ensure that all aspects of the trial are operationally feasible and should avoid unnecessary complexity, procedures and data collection. Protocols, case report forms, and other operational documents should be clear, concise and consistent.
  • The sponsor should ensure oversight of any trial-related duties and functions carried out on its behalf. The sponsor should develop a systematic, prioritized, risk-based appraoch to monitoring clinical trials. A combination of on-site and centralized monitoring activities may be appropriate. The sponsor should document the rationale for the chosen monitoring strategy (e.g. in the monitoring plan).

These changes will impact how we manage clincial development operationally with quality embedded through operational excellence not a goal but an expectation.

In three parallel themes, Data Management, Clinical Operations and Statistics will be examined through presentation, case studies and discussion focusing on how to achieve operational excellence. During a joint plenary session, topics that bind both groups will be discussed: Risk-based Monitoring, the status of eSource and independent 3rd parties, and Quality Management in Outsourcing.

Who should attend?

  • Professional working with clinical operations
  • Clinical data management professionals
  • Monitors
  • Statisticians
  • Inspectors
  • Process optimization leads and managers
  • Trial managers
  • Field monitors
  • Site representetatives, Site leads
  • Project data managers
  • Professionals working in the interface between CROs and Sponsors
  • Vendor managers
  • Pharma IT professionals (working in highly regulated environment)

For further information, please visit:
http://www.diaglobal.org/en/conference-listing/meetings/2016/10/9th-annual-clinical-forum-13-14-oct-2016-dusseldorf-germany

About DIA
For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global players a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation.

DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, the Middle East, and Africa (Basel, Switzerland); and Asia (Beijing, China; Mumbai, India; and, Tokyo, Japan).

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...